Compare DOMH & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMH | THAR |
|---|---|---|
| Founded | 1967 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.0M | 83.1M |
| IPO Year | N/A | 2022 |
| Metric | DOMH | THAR |
|---|---|---|
| Price | $3.97 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 265.7K | ★ 522.9K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | ★ 14.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 9.19 | N/A |
| Revenue | ★ $99,588,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.42 | ★ N/A |
| Revenue Growth | ★ 691.07 | N/A |
| 52 Week Low | $0.83 | $0.95 |
| 52 Week High | $13.58 | $9.08 |
| Indicator | DOMH | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 47.08 |
| Support Level | $3.73 | $2.36 |
| Resistance Level | $5.00 | $2.55 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 19.22 | 68.73 |
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.